MedPath

Topiramate’s effectiveness on weight reduction in overweight/obese persons with Schizophrenia

Phase 4
Completed
Conditions
Schizophrenia, Obesity, Overweight
Registration Number
SLCTR/2017/003
Lead Sponsor
Department of Psychiatry
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Not specified
Target Recruitment
Not specified
Inclusion Criteria

1. Diagnosis of schizophrenia (International Classification of Diseases (ICD), 10th edition)
2. Age 18 years and above
3. Capacity to give informed consent (as determined by assessment of an external psychiatrist)
4. Body Mass Index above the cut-off for Asians, which is 23 kg/m2 by the World Health Organization

Exclusion Criteria

1. Diabetes mellitus
2. Hypertension
3. Dyslipidaemia
4. Patients on other weight reducing agents
5. Patients with a significant loss of appetite leading to loss of more than 10% of body weight over a period of six months
6. Patients with difficulty in swallowing
7. Pregnant and lactating females

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.